MANF Antibody

What is MANF and where is it primarily expressed in normal tissue?

MANF is a neurotrophic factor that shows protective effects in various injury models, particularly cerebral ischemia. In uninjured rodent brains, MANF protein is expressed almost exclusively in neurons . During embryonic development, MANF expression can be detected in all three germ layers (ectoderm, endoderm, and mesoderm) as early as E7.5, but is notably absent in extraembryonic ectoderm . MANF is also highly expressed in brain neurons regulating energy homeostasis and appetite, as well as in hypothalamic nuclei producing hormones .

Methodology for detection: When studying MANF expression patterns, researchers should consider using validated antibodies in combination with gene expression analysis techniques such as LacZ staining in heterozygous MANF+/- models containing a β-galactosidase reporter gene .

How do I validate the specificity of my MANF antibody?

Antibody validation is critical for ensuring experimental reliability. The gold standard approach is to test the antibody on tissues from MANF knockout models:

• Western blot analysis should show a specific band at approximately 17-24 kDa in wild-type samples that is absent in MANF knockout samples

• Immunohistochemistry should show positive staining in wild-type tissue that is absent in MANF knockout tissue

• ELISA assays using the antibody should not give signals when using MANF knockout tissues

For example, researchers have confirmed antibody specificity by demonstrating no background detection in tissues of Manf−/− mice and by showing the absence of staining in E9.5 Manf−/− embryos compared to positive staining in wild-type embryos .

What are the recommended protocols for MANF immunohistochemistry?

Based on protocols from published research, the following methodology is recommended:

• For paraffin-embedded samples:

  • Cut tissues into 4 μm sections and mount on microscope slides

  • Deparaffinize and perform antigen retrieval using 10 mM citrate buffer, pH 6.0

  • Block endogenous peroxidase with 0.3% hydrogen peroxide in methanol

  • Block non-specific binding with 10% normal goat serum in 0.1% Tween-20 in TBS

  • For additional blocking, use avidin and biotin

  • Incubate with primary anti-MANF antibody (e.g., 1:800 dilution) in 1.5% normal goat serum in 0.1% TBS-T overnight at 4°C

  • Incubate with biotinylated secondary antibody followed by avidin-biotin complex

For double immunohistochemistry (detecting MANF with other markers like PGP9.5), follow standard protocols for co-staining, ensuring proper controls to prevent cross-reactivity .

How does MANF expression change in pathological conditions such as ischemic stroke?

During infarct progression, cerebral MANF expression patterns in both human and rat brains shift dramatically:

• In healthy tissue: MANF is primarily expressed in neurons

• Post-stroke: Expression shifts to inflammatory cells, with intense MANF immunoreactivity in phagocytic microglia/macrophages in the ischemic territory

• Temporal dynamics:

  • Peaks at two weeks post-stroke in human tissue

  • Peaks at one week post-stroke in rat ischemic cortex

Methodological considerations:

• When studying time-dependent changes, establish a consistent timeline with multiple sampling points

• Use double immunofluorescence with cell-type specific markers to accurately identify MANF-expressing cells

• Verify findings using MANF conditional knockout models lacking MANF from specific cell types (neurons, astrocytes, oligodendrocytes)

What are the optimized protocols for detecting MANF using ELISA?

For quantitative measurement of MANF in tissue or serum samples, sandwich ELISA techniques have been validated with the following methodology:

Mouse MANF ELISA protocol:

• Coating:

  • Coat 96-well MaxiSorp plates with goat anti-human MANF antibody (AF3748, R&D Systems) in 50 mM carbonate buffer, pH 9.6

• Blocking and sample preparation:

  • Block with 1% casein-PBST (PBS with 0.05% Tween 20)

  • For serum samples: Dilute 1:40 for quantitation

  • Prepare standard curve using recombinant MANF (31.25-1000 pg/ml range)

• Detection:

  • Incubate samples and standards overnight at 4°C

  • After washing, detect bound MANF using rabbit anti-MANF antibody (LS-B2688, LSBio)

  • Incubate with HRP-conjugated anti-rabbit IgG secondary antibody

  • Develop color using DuoSet ELISA Development System

  • Read absorbance at 450 nm and 540 nm

Assay characteristics:

• Dynamic range: 31.25–1000 pg/ml

• Sensitivity: 29 pg/ml

• No signal detected from MANF knockout tissues

What controls should be included when using MANF antibodies for Western blot analysis?

When conducting Western blot with MANF antibodies, the following controls are essential:

Methodological notes:

• For optimal results, use PVDF membrane

• Western blot should be conducted under reducing conditions

• Use 1 μg/mL concentration of primary antibody (such as Goat Anti-Human MANF Antigen Affinity-purified Polyclonal Antibody)

How can I quantify changes in MANF expression in serum samples following experimental stroke?

For monitoring changes in circulating MANF levels following stroke, the following approach is recommended:

• Sample collection protocol:

  • Collect terminal blood samples by cardiac puncture at defined timepoints post-stroke (e.g., 1h, 6h, 24h, 48h)

  • Allow blood to coagulate for at least 30 min

  • Separate serum by centrifugation at 2,000g at room temperature for 10 min

  • Store samples at -80°C until analysis

• Quantification using ELISA:

  • Use validated MANF ELISA as described in question 2.2

  • Dilute serum samples 1:40 before analysis

  • Include appropriate standards for accurate quantification

• Data analysis considerations:

  • Compare with pre-stroke baseline or control animal samples

  • Consider individual variability by using sufficient sample sizes

  • Analyze time-dependent changes to identify peak release periods

How do MANF antibody pharmacokinetics differ from typical monoclonal antibodies?

While specific pharmacokinetic data for MANF antibodies is not provided in the search results, general principles for monoclonal antibodies can be applied with certain considerations:

Based on a model-based meta-analysis of monoclonal antibodies:

• Typical population parameter estimates for systemic clearance: 0.20 L/day

• Typical central volume of distribution: 3.6 L

• Intersubject variability: 31% for clearance, 34% for volume of distribution

• Random residual error: 14%

The pharmacokinetics of monoclonal antibodies can be described by a 2-compartment model with:

• First-order elimination from the central compartment

• First-order absorption from a depot compartment (for SC administration)

When designing PK studies for MANF antibodies, researchers should consider:

• Rich sampling designs (22 samples/subject) for detailed profiles

• Minimal designs for population PK (5 samples/subject)

• Optimal designs for both non-compartmental analysis and population PK (10 samples/subject)

What methodological approaches can resolve contradictory findings regarding MANF expression in different neural cell types?

When facing contradictory results regarding MANF expression patterns:

• Use multiple antibody validation approaches:

  • Test multiple antibodies from different manufacturers/clones

  • Always validate with knockout controls

  • Combine immunodetection with mRNA analysis (qPCR, in situ hybridization)

• Employ cell-type specific markers in co-localization studies:

  • For neurons: Use PGP9.5 as demonstrated in double immunohistochemistry studies

  • For microglia/macrophages: Use cell-type specific markers in double immunofluorescence studies

  • For other neural cells: Use appropriate markers for astrocytes, oligodendrocytes, etc.

• Utilize conditional knockout models:

  • Employ models lacking MANF gene and protein specifically from:

    • Neuronal stem cells

    • Neurons

    • Astrocytes

    • Oligodendrocytes

• Consider developmental and pathological context:

  • MANF expression changes significantly during development and after injury

  • Sampling timepoints are critical for consistent results

  • Experimental stroke models show dramatic shifts in expression patterns

Why might I be getting non-specific staining with my MANF antibody in immunohistochemistry?

Non-specific staining can result from several factors. Here's a methodological approach to troubleshooting:

• Insufficient blocking:

  • Implement multi-step blocking protocols as used in validated studies:

    • Block with 10% normal goat serum in 0.1% Tween-20 in TBS

    • Follow with avidin and biotin blocking

    • Include 1.5% normal goat serum with primary antibody incubation

• Antibody concentration issues:

  • Titrate antibody concentration (start with validated dilutions like 1:800)

  • Extend primary antibody incubation time (overnight at 4°C is recommended)

• Antigen retrieval problems:

  • Ensure proper antigen retrieval with 10 mM citrate buffer, pH 6.0

  • Optimize heating time and temperature for your specific tissue type

• Cross-reactivity:

  • Verify antibody specificity with knockout controls

  • Consider using monoclonal antibodies for higher specificity

  • Test antibody on known negative tissues

What are the critical steps for optimizing MANF detection in Western blot analysis?

For optimal Western blot results:

• Sample preparation:

  • Use appropriate lysis buffers with protease inhibitors

  • Standardize protein quantification methods

  • Load consistent amounts (typically 10-20 μg of total protein)

• Electrophoresis and transfer conditions:

  • Use reducing conditions

  • Expected MANF band size is approximately 17 kDa in standard Western blot

  • In Simple Western systems, MANF may appear at approximately 24 kDa

• Antibody selection and dilution:

  • Validated concentration: 1 μg/mL for primary antibody

  • HRP-conjugated secondary antibodies show good results

  • Consider using pre-validated antibody pairs known to work in Western applications

• Detection systems:

  • Standard chemiluminescence works well for MANF detection

  • Simple Western systems can provide highly quantitative results

• Troubleshooting weak signals:

  • Increase protein loading

  • Extend primary antibody incubation time

  • Use more sensitive detection systems

  • Consider concentrating samples if working with dilute sources

How should I quantify and statistically analyze MANF expression changes in tissue sections?

For quantitative analysis of MANF expression in tissue sections:

• Image acquisition:

  • Capture multiple representative fields per sample

  • Use consistent microscope settings across all samples

  • Include internal controls in each imaging session

• Quantification approaches:

  • For cell counting: Count MANF-positive cells as a percentage of total cells or specific cell types

  • For intensity measurements: Use mean optical density or integrated optical density

  • For co-localization: Calculate Pearson's correlation coefficient or Manders' overlap coefficient

• Statistical analysis:

  • Present data as mean ± SEM

  • For comparing two groups: Use Student's t-test as demonstrated in published studies

  • For multiple group comparisons: Use ANOVA with appropriate post-hoc tests

  • Use GraphPad Prism or similar software for analysis and visualization

• Ensuring reproducibility:

  • Analyze samples in a blinded fashion

  • Include biological replicates (separate animals/patients)

  • Report specific statistical methods, sample sizes, and p-values

What are the best approaches for analyzing MANF ELISA data from serum samples?

When analyzing MANF ELISA data from serum samples:

• Standard curve preparation:

  • Use recombinant MANF standards within the validated range (31.25-1000 pg/ml)

  • Create a minimum of 6-point standard curve with duplicate measurements

  • Use appropriate curve-fitting methods (typically 4-parameter logistic regression)

• Sample analysis:

  • Analyze all samples in duplicate at minimum

  • Dilute samples appropriately (1:40 dilution has been validated for serum)

  • Include quality control samples with known MANF concentrations

• Addressing variability:

  • Calculate intra-assay and inter-assay coefficients of variation

  • Accept CV values <15% for reliable quantification

  • Rerun samples with high variability between duplicates

• Data interpretation:

  • Consider the assay's lower limit of detection (29 pg/ml is reported)

  • For values below detection limit, report as "below LLOD" rather than zero

  • Account for dilution factors in final concentration calculations